Clarius Group LLC decreased its holdings in Novartis AG (NYSE:NVS) by 2.6% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,507 shares of the company’s stock after selling 146 shares during the quarter. Clarius Group LLC’s holdings in Novartis were worth $471,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also made changes to their positions in the company. Phoenix Wealth Advisors purchased a new stake in Novartis in the fourth quarter worth $27,000. Regent Peak Wealth Advisors LLC purchased a new stake in Novartis in the fourth quarter worth $34,000. Addison Advisors LLC purchased a new stake in Novartis in the fourth quarter worth $40,000. Northwest Investment Counselors LLC purchased a new stake in Novartis in the first quarter worth $41,000. Finally, Veriti Management LLC bought a new position in Novartis in the fourth quarter worth $42,000. 9.86% of the stock is owned by institutional investors.
A number of research firms have issued reports on NVS. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Novartis in a report on Wednesday, April 28th. Barclays restated an “underweight” rating on shares of Novartis in a report on Friday, January 22nd. Sanford C. Bernstein initiated coverage on Novartis in a report on Monday, March 22nd. They set a “market perform” rating for the company. UBS Group reiterated a “buy” rating on shares of Novartis in a report on Monday, April 19th. Finally, Oddo Bhf raised Novartis from a “neutral” rating to an “outperform” rating in a research report on Wednesday, April 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $108.50.
Novartis (NYSE:NVS) last posted its quarterly earnings data on Monday, April 26th. The company reported $1.52 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.54 by ($0.02). Novartis had a net margin of 14.71% and a return on equity of 24.39%. The business had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.63 billion. During the same quarter in the previous year, the firm earned $1.56 EPS. Novartis’s revenue was up 1.0% compared to the same quarter last year. Equities analysts anticipate that Novartis AG will post 5.8 EPS for the current fiscal year.
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products.
Featured Story: Hedge Funds – Risk or Reward?
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.